Federal probe finds that just two drugs account for 90% of Medicaid rebate losses
Fierce Pharma ---------- After discovering that Mylan had avoided paying Medicaid tens of millions of dollars in rebates by misclassifying its EpiPen, Congress asked the agency to determine how wide-ranging the problem was. It now has its answer. The number of misclassified drugs is small, but the cost to the cash-strapped Medicaid program is big: hundreds of millions of dollars a year, and most of that comes from just a few drugs. While only 3% of the 30,000 drugs reviewed were misclassified, the report found that the cost to Medicaid for the 10 potentially misclassified drugs with the highest total reimbursement, ran to $1.3 billion between 2012 and 2016. To learn more click on the picture below to read the article.